Lantern Pharma (LTRN) Tops Q2 EPS by 13c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.40), $0.13 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Freedom Capital Starts Hut 8 Mining Corp. (HUT) at Buy
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance